Ioanna Michalopoulou shares her views on the transformative changes brought about by Covid19 in Business and Law in Greece, with esteemed colleagues
The White Paper on Artificial Intelligence published on February 19th by the European Commission presents some important building block policy options. These enable a trustworthy and secure development of artificial intelligence in the EU, fully respecting the presiding values and the fundamental rights of its citizens. The enormous volume of data which has already been
Our firm’s approach on Genomic research and data protection in view of the CRISPR technology. You may read our article below: “This article first appeared on the website of the Healthcare and Life Sciences Law Committee of the Legal Practice Division of the International Bar Association, and is reproduced by kind permission of the
legal breakthrough
Michalopoulou & Associates successfully represented a medical devices company on dispute arising from the enforcement of a monetary amount on behalf of EOPYY related to the reimbursement of specific expendable medical supplies (medical dressings). Our team successfully proved before the competent court that the enforced monetary amount did not include sufficient and unambiguous justification in
Ms Michalopoulou and Ms Chatziantoniou have contributed to this year’s edition on the compliance of pharmaceutical companies with the local and European legislation and in particular the current legislative framework in Greece for providing information prior authorization of a medicinal product, advertising to healthcare professionals (HCPs), gifts and hospitality, regarding transparency and disclosure status as
Ms. Michalopoulou participated in the 15th Panhellenic Congress of Nutrition – Dietetics & 4th Panhellenic Conference on Clinical Nutrition & Metabolism held on December 14th, 2019 at the Athens International Conference Center. The theme of her speech was: “Personalized Nutrition during which she analyzed how the current legal framework is shaped in the light of
Οur law firm has been invited by the National School of Public Health to participate in its Panhellenic Conference for 2019 and to contribute to the Big Data Unit on Monday 9/12/2019. Our talk was entitled “Small Data is Big Data ‘in Disguise’ – Legal and Ethical Concerns for the Health Sector” focusing on the
Mrs. Michalopoulou has participated at the 8th Panhellenic Conference on Procurement & Supply Management held in Athens on November 28th, 2019 and analyzed ‘The latest GDPR developments and its application in Supplies and Logistics’. She emphasized on the legal provisions that procurement departments and supply companies must practice in order to transform their businesses in
The Cancer & Personalized Medicine Conference 2019 was successfully held on Thursday October 17th, 2019 at the Divani Caravel Hotel where Mrs. Ioanna Michalopoulou was invited to participate in its 3rd panel and analysed the issue of ‘Legal Aspects regarding the use of innovative medicines in a digitizing world’ and had the opportunity to present

Pharma Transformation 2019

Our law firm also contributed this year as a research associate to the 3rd Pharma Transformation Day: Compliance in a Digital Era Mrs. Michalopoulou has participated in the section “Digital Transformation: The Role of Big Data and Artificial Intelligence” and emphasized on the legal issues and ethical dilemmas that the health industry is calling

Food Safety Conference 2019

During the works of the Food Safety Conference 2019 our lawfirm participated in the section “Exploiting Advanced Technology Solutions”. Ioanna Michalopoulou focused on the issue of Novel Foods and the achievement of a high level of credibility in all parts of the supply chain, producer, distributor as well as reviewing tools and approaches to assess
Hospital Medicine 2019 was successfully hosted on Wednesday June 5th 2019 at the Divani Caravel hotel where Mrs. Ioanna Michalopoulou was invited to participate in her 3rd unit on “Medical Devices” and had the opportunity to present the changes of the new Regulatory framework for medical devices (EU 2017/745 MDR and EU 2017/746 IVDR), their